Bacillus anthracis antigens, vaccine compositions, and related methods
First Claim
Patent Images
1. An isolated antigen comprising a component of Bacillus anthracis virulence factor fused to a LicKM protein;
- wherein the virulence factor component comprises at least one domain having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.;
4, SEQ ID NO;
6, SEQ ID NO;
15, amino acid residues 1-137 of SEQ ID NO.;
2, amino acid residues 251-263 of SEQ ID NO.;
2, amino acid residues 138-250 of SEQ ID NO.;
2, amino acid residues 264-283 of SEQ ID NO.;
2, amino acid residues 429-551 of SEQ ID NO.;
2, amino acid residues 306-385 of SEQ ID NO.;
2, amino acid residues 552-776 of SEQ ID NO.;
2, amino acid residues 1-250 of SEQ ID NO.;
1, amino acid residues 251-456 of SEQ ID NO.;
1, amino acid residues 477-595 of SEQ ID NO.;
1, and amino acid residues 608-735 of SEQ ID NO.;
1; and
wherein the LicKM protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO.;
8 or SEQ ID NO.;
10.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus anthracis. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
112 Citations
39 Claims
-
1. An isolated antigen comprising a component of Bacillus anthracis virulence factor fused to a LicKM protein;
-
wherein the virulence factor component comprises at least one domain having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.;
4, SEQ ID NO;
6, SEQ ID NO;
15, amino acid residues 1-137 of SEQ ID NO.;
2, amino acid residues 251-263 of SEQ ID NO.;
2, amino acid residues 138-250 of SEQ ID NO.;
2, amino acid residues 264-283 of SEQ ID NO.;
2, amino acid residues 429-551 of SEQ ID NO.;
2, amino acid residues 306-385 of SEQ ID NO.;
2, amino acid residues 552-776 of SEQ ID NO.;
2, amino acid residues 1-250 of SEQ ID NO.;
1, amino acid residues 251-456 of SEQ ID NO.;
1, amino acid residues 477-595 of SEQ ID NO.;
1, and amino acid residues 608-735 of SEQ ID NO.;
1; andwherein the LicKM protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO.;
8 or SEQ ID NO.;
10. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26)
-
-
2. An immunogenic composition comprising an antigen comprising a component of Bacillus anthracis virulence factor fused to a LicKM protein and a pharmaceutically acceptable carrier;
-
wherein the virulence factor component comprises at least one domain having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.;
4, SEQ ID NO;
6, SEQ ID NO;
15, amino acid residues 1-137 of SEQ ID NO.;
2, amino acid residues 251-263 of SEQ ID NO.;
2, amino acid residues 138-250 of SEQ ID NO.;
2, amino acid residues 264-283 of SEQ ID NO.;
2, amino acid residues 429-551 of SEQ ID NO.;
2, amino acid residues 306-385 of SEQ ID NO.;
2, amino acid residues 552-776 of SEQ ID NO.;
2, amino acid residues 1-250 of SEQ ID NO.;
1, amino acid residues 251-456 of SEQ ID NO.;
1, amino acid residues 477-595 of SEQ ID NO.;
1, and amino acid residues 608-735 of SEQ ID NO.;
1;wherein the LicKM protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO.;
8 or SEQ ID NO.;
10;and wherein the composition is capable of eliciting an immune response upon administration to a subject. - View Dependent Claims (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
-
3. An immunogenic composition comprising:
- at least two antigens, each of which comprises a component of Bacillus anthracis virulence factor having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.;
4, SEQ ID NO;
6, SEQ ID NO;
15, amino acid residues 1-137 of SEQ ID NO.;
2, amino acid residues 251-263 of SEQ ID NO.;
2, amino acid residues 138-250 of SEQ ID NO.;
2, amino acid residues 264-283 of SEQ ID NO.;
2, amino acid residues 429-551 of SEQ ID NO.;
2, amino acid residues 306-385 of SEQ ID NO.;
2, amino acid residues 552-776 of SEQ ID NO.;
2, amino acid residues 1-250 of SEQ ID NO.;
1, amino acid residues 251-456 of SEQ ID NO.;
1, amino acid residues 477-595 of SEQ ID NO.;
1, and amino acid residues 608-735 of SEQ ID NO.;
1, wherein at least one of the antigens further comprises a LicKM protein, and wherein the LicKM protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO.;
8 or SEQ ID NO.;
10. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 38, 39)
- at least two antigens, each of which comprises a component of Bacillus anthracis virulence factor having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.;
-
16. A method for inducing an immune response in a subject, comprising administering to a subject an effective amount of an anti-anthrax immunogenic composition, wherein the administration is sufficient to stimulate production of antigen specific antibodies or stimulate a cellular immune response by the subject;
- thereby inducing a protective immune response;
wherein the immunogenic composition comprises an antigen comprising a component of Bacillus anthracis virulence factor fused to a LicKM protein, wherein the LicKM protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO.;
8 or SEQ ID NO.;
10; andwherein the virulence factor component comprises at least one domain having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.;
4, SEQ ID NO;
6, SEQ ID NO;
15, amino acid residues 1-137 of SEQ ID NO.;
2, amino acid residues 251-263 of SEQ ID NO.;
2, amino acid residues 138-250 of SEQ ID NO.;
2, amino acid residues 264-283 of SEQ ID NO.;
2, amino acid residues 429-551 of SEQ ID NO.;
2, amino acid residues 306-385 of SEQ ID NO.;
2, amino acid residues 552-776 of SEQ ID NO.;
2, amino acid residues 1-250 of SEQ ID NO.;
1, amino acid residues 251-456 of SEQ ID NO.;
1, amino acid residues 477-595 of SEQ ID NO.;
1, and amino acid residues 608-735 of SEQ ID NO.;
1.
- thereby inducing a protective immune response;
-
17. A method for inducing an immune response in a subject, comprising administering to a subject an effective amount of an anti-anthrax immunogenic composition, wherein the immunogenic composition comprise at least two antigens, each of which comprises a component of Bacillus anthracis virulence factor having an amino acid sequence with at least 95% identity to a sequence selected from the group consisting of SEQ ID NO.:
- 4, SEQ ID NO;
6, SEQ ID NO;
15, amino acid residues 1-137 of SEQ ID NO.;
2, amino acid residues 251-263 of SEQ ID NO.;
2, amino acid residues 138-250 of SEQ ID NO.;
2, amino acid residues 264-283 of SEQ ID NO.;
2, amino acid residues 429-551 of SEQ ID NO.;
2, amino acid residues 306-385 of SEQ ID NO.;
2, amino acid residues 552-776 of SEQ ID NO.;
2, amino acid residues 1-250 of SEQ ID NO.;
1, amino acid residues 251-456 of SEQ ID NO.;
1, amino acid residues 477-595 of SEQ ID NO.;
1, and amino acid residues 608-735 of SEQ ID NO.;
1, wherein at least one of the antigens further comprises a LicKM protein, wherein the LicKM protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO.;
8 or SEQ ID NO.;
10, and wherein the administration is sufficient to stimulate production of antigen specific antibodies or stimulate a cellular immune response by the subject;
thereby inducing a protective immune response.
- 4, SEQ ID NO;
Specification